1.51 USD
-0.05 (-3.21%)
1.51 USD
0 (0%)
LAB gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. While LAB seems to be doing ok healthwise, there are quite some concerns on its profitability. LAB has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- In the past year LAB has reported negative net income.
- In the past year LAB has reported a negative cash flow from operations.
- In the past 5 years LAB always reported negative net income.
- LAB had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- LAB's Return On Assets of -23.77% is on the low side compared to the rest of the industry. LAB is outperformed by 70.18% of its industry peers.
- With a Return On Equity value of -32.09%, LAB is not doing good in the industry: 61.40% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.77% | ||
| ROE | -32.09% | ||
| ROIC | N/A |
ROA(3y)-34.01%
ROA(5y)-27.97%
ROE(3y)-55.9%
ROE(5y)-53.68%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- LAB's Gross Margin of 47.94% is in line compared to the rest of the industry. LAB outperforms 49.12% of its industry peers.
- LAB's Gross Margin has declined in the last couple of years.
- The Profit Margin and Operating Margin are not available for LAB so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.94% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.13%
GM growth 5Y-2.51%
2. Health
2.1 Basic Checks
- LAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for LAB has been increased compared to 1 year ago.
- The number of shares outstanding for LAB has been increased compared to 5 years ago.
- The debt/assets ratio for LAB has been reduced compared to a year ago.
2.2 Solvency
- LAB has an Altman-Z score of -0.44. This is a bad value and indicates that LAB is not financially healthy and even has some risk of bankruptcy.
- With a Altman-Z score value of -0.44, LAB is not doing good in the industry: 78.95% of the companies in the same industry are doing better.
- A Debt/Equity ratio of 0.00 indicates that LAB is not too dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.00, LAB is in the better half of the industry, outperforming 73.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.44 |
ROIC/WACCN/A
WACC11.17%
2.3 Liquidity
- A Current Ratio of 4.38 indicates that LAB has no problem at all paying its short term obligations.
- With a decent Current ratio value of 4.38, LAB is doing good in the industry, outperforming 70.18% of the companies in the same industry.
- A Quick Ratio of 4.14 indicates that LAB has no problem at all paying its short term obligations.
- LAB has a better Quick ratio (4.14) than 75.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.38 | ||
| Quick Ratio | 4.14 |
3. Growth
3.1 Past
- LAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.11%, which is quite impressive.
- Looking at the last year, LAB shows a very negative growth in Revenue. The Revenue has decreased by -17.37% in the last year.
- LAB shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.28% yearly.
EPS 1Y (TTM)52.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.57%
Revenue 1Y (TTM)-17.37%
Revenue growth 3Y10.13%
Revenue growth 5Y8.28%
Sales Q2Q%-56.52%
3.2 Future
- LAB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.34% yearly.
- The Revenue is expected to decrease by -16.16% on average over the next years. This is quite bad
EPS Next Y52.25%
EPS Next 2Y30.97%
EPS Next 3Y20.34%
EPS Next 5YN/A
Revenue Next Year-53.07%
Revenue Next 2Y-31.76%
Revenue Next 3Y-21.36%
Revenue Next 5Y-16.16%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for LAB. In the last year negative earnings were reported.
- Also next year LAB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as LAB's earnings are expected to grow with 20.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.97%
EPS Next 3Y20.34%
5. Dividend
5.1 Amount
- LAB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
1.51
-0.05 (-3.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)01-08 2026-01-08/amc
Earnings (Next)05-04 2026-05-04
Inst Owners76.79%
Inst Owner ChangeN/A
Ins Owners2.42%
Ins Owner Change25.36%
Market Cap580.70M
Revenue(TTM)128.83M
Net Income(TTM)-128.25M
Analysts77.14
Price Target1.58 (4.64%)
Short Float %2.75%
Short Ratio5.63
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-36.7%
Min EPS beat(2)-62.02%
Max EPS beat(2)-11.39%
EPS beat(4)1
Avg EPS beat(4)-23.28%
Min EPS beat(4)-62.02%
Max EPS beat(4)7.59%
EPS beat(8)2
Avg EPS beat(8)-42.02%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)5.94%
Min Revenue beat(2)4.33%
Max Revenue beat(2)7.56%
Revenue beat(4)4
Avg Revenue beat(4)5.02%
Min Revenue beat(4)0.73%
Max Revenue beat(4)7.56%
Revenue beat(8)6
Avg Revenue beat(8)1.89%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-12.68%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-27.27%
EPS NY rev (1m)0%
EPS NY rev (3m)-18.18%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)-4.18%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.96%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 4.51 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.45 | ||
| P/tB | 1.45 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.34
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0.33
BVpS1.04
TBVpS1.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.77% | ||
| ROE | -32.09% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.94% | ||
| FCFM | N/A |
ROA(3y)-34.01%
ROA(5y)-27.97%
ROE(3y)-55.9%
ROE(5y)-53.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.13%
GM growth 5Y-2.51%
F-Score4
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 82.18% | ||
| Cap/Sales | 8.7% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.38 | ||
| Quick Ratio | 4.14 | ||
| Altman-Z | -0.44 |
F-Score4
WACC11.17%
ROIC/WACCN/A
Cap/Depr(3y)31.23%
Cap/Depr(5y)51.75%
Cap/Sales(3y)3.79%
Cap/Sales(5y)6.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.57%
EPS Next Y52.25%
EPS Next 2Y30.97%
EPS Next 3Y20.34%
EPS Next 5YN/A
Revenue 1Y (TTM)-17.37%
Revenue growth 3Y10.13%
Revenue growth 5Y8.28%
Sales Q2Q%-56.52%
Revenue Next Year-53.07%
Revenue Next 2Y-31.76%
Revenue Next 3Y-21.36%
Revenue Next 5Y-16.16%
EBIT growth 1Y10.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year66.04%
EBIT Next 3Y24.99%
EBIT Next 5Y18.51%
FCF growth 1Y-89.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-80.15%
OCF growth 3YN/A
OCF growth 5YN/A
STANDARD BIOTOOLS INC / LAB FAQ
What is the ChartMill fundamental rating of STANDARD BIOTOOLS INC (LAB) stock?
ChartMill assigns a fundamental rating of 2 / 10 to LAB.
Can you provide the valuation status for STANDARD BIOTOOLS INC?
ChartMill assigns a valuation rating of 1 / 10 to STANDARD BIOTOOLS INC (LAB). This can be considered as Overvalued.
Can you provide the profitability details for STANDARD BIOTOOLS INC?
STANDARD BIOTOOLS INC (LAB) has a profitability rating of 0 / 10.
Can you provide the financial health for LAB stock?
The financial health rating of STANDARD BIOTOOLS INC (LAB) is 4 / 10.